IS8526A - CRF viðtakamótlyf og aðferðir tengdar þeim - Google Patents

CRF viðtakamótlyf og aðferðir tengdar þeim

Info

Publication number
IS8526A
IS8526A IS8526A IS8526A IS8526A IS 8526 A IS8526 A IS 8526A IS 8526 A IS8526 A IS 8526A IS 8526 A IS8526 A IS 8526A IS 8526 A IS8526 A IS 8526A
Authority
IS
Iceland
Prior art keywords
receptor antagonists
associated methods
crf receptor
crf
methods
Prior art date
Application number
IS8526A
Other languages
English (en)
Inventor
Deborah H Slee
John Edward Tellew
John P Williams
Xiaohu Zhang
Zhiyong Luo
Original Assignee
Smithkline Beecham Cork Ltd
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd, Neurocrine Biosciences Inc filed Critical Smithkline Beecham Cork Ltd
Publication of IS8526A publication Critical patent/IS8526A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS8526A 2003-12-22 2006-07-11 CRF viðtakamótlyf og aðferðir tengdar þeim IS8526A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53203103P 2003-12-22 2003-12-22

Publications (1)

Publication Number Publication Date
IS8526A true IS8526A (is) 2006-07-11

Family

ID=34738733

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8526A IS8526A (is) 2003-12-22 2006-07-11 CRF viðtakamótlyf og aðferðir tengdar þeim

Country Status (19)

Country Link
US (1) US7737154B2 (is)
EP (1) EP1697374B1 (is)
JP (1) JP4926720B2 (is)
KR (1) KR20070009537A (is)
CN (1) CN1938309B (is)
AR (1) AR046967A1 (is)
AU (1) AU2004309168B2 (is)
BR (1) BRPI0417943A (is)
CA (1) CA2550948A1 (is)
IL (1) IL176350A0 (is)
IS (1) IS8526A (is)
MA (1) MA29984B1 (is)
MY (1) MY143499A (is)
NO (1) NO20063230L (is)
NZ (1) NZ547990A (is)
RU (1) RU2394035C2 (is)
TW (1) TW200530242A (is)
WO (1) WO2005063755A1 (is)
ZA (1) ZA200604574B (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
DE602005014375D1 (de) * 2004-10-19 2009-06-18 Neurocrine Biosciences Inc Crf-rezeptor-antagonisten und zugehörige verfahren
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
CA2663511C (en) 2006-09-20 2012-12-04 Eli Lilly And Company Thiazole pyrazolopyrimidines as crf1 receptor antagonists
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
KR100854679B1 (ko) * 2007-02-03 2008-08-27 김기형 심플 서비스 로케이션 프로토콜 네트워크 시스템 및 이를구성하는 에이전트.
EP2282998B1 (en) * 2008-04-21 2014-09-10 Albemarle Corporation Processes for producing n-alkylpyrazole
JP5748777B2 (ja) * 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
CN104884449A (zh) 2012-10-31 2015-09-02 拜尔农作物科学股份公司 作为害虫防治剂的新的杂环化合物
AU2015245786B2 (en) * 2014-04-10 2018-03-15 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Analogues of 4H-pyrazolo[1,5-a]benzimidazole compound as PARP inhibitors
CN118845788A (zh) 2017-08-14 2024-10-29 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
WO2022020888A1 (en) * 2020-07-27 2022-02-03 Esfam Biotech Pty Ltd Compounds
CN118948857A (zh) 2020-08-12 2024-11-15 云杉生物科学公司 用于治疗多囊卵巢综合征的方法和组合物
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE880523T1 (de) * 1996-02-07 2002-07-04 Janssen Pharmaceutica N.V., Beerse Pyrazolopyrimidine als crf rezeptor-antagonisten
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) * 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
ES2273369T3 (es) 1996-08-28 2007-05-01 Pfizer Inc. Derivados 6,5 heterobiciclicos sustituidos.
AU734009B2 (en) * 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
EP1049699B1 (en) * 1998-01-28 2004-04-21 Bristol-Myers Squibb Pharma Company Pyrazolotriazines as crf antagonists
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
EP1218381B1 (en) 1999-09-30 2006-12-06 Neurogen Corporation AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
CA2446514A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
US7462622B2 (en) * 2001-06-12 2008-12-09 Glaxo Group Limited Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
DE602004005960T2 (de) * 2003-01-16 2008-01-17 Sb Pharmco Puerto Rico Inc. Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
JP2007515474A (ja) * 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
DE102004008807A1 (de) * 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
DE602005014375D1 (de) * 2004-10-19 2009-06-18 Neurocrine Biosciences Inc Crf-rezeptor-antagonisten und zugehörige verfahren
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
ZA200604574B (en) 2007-11-28
WO2005063755A1 (en) 2005-07-14
JP2007515472A (ja) 2007-06-14
KR20070009537A (ko) 2007-01-18
EP1697374A1 (en) 2006-09-06
IL176350A0 (en) 2006-10-05
RU2006126675A (ru) 2008-01-27
US7737154B2 (en) 2010-06-15
NZ547990A (en) 2010-04-30
AR046967A1 (es) 2006-01-04
CA2550948A1 (en) 2005-07-14
AU2004309168A1 (en) 2005-07-14
CN1938309B (zh) 2011-11-09
JP4926720B2 (ja) 2012-05-09
NO20063230L (no) 2006-09-12
MY143499A (en) 2011-05-31
MA29984B1 (fr) 2008-12-01
AU2004309168B2 (en) 2009-04-23
EP1697374B1 (en) 2012-08-29
RU2394035C2 (ru) 2010-07-10
TW200530242A (en) 2005-09-16
BRPI0417943A (pt) 2007-04-17
US20070287705A1 (en) 2007-12-13
CN1938309A (zh) 2007-03-28

Similar Documents

Publication Publication Date Title
IS8190A (is) Ný P2X7 viðtakamótlyf og notkun þeirra
IS8032A (is) Kannabinóíð viðtakabindlar og notkun þeirra
IS8054A (is) Kannabinóíð viðtaka bindlar og notkun þeirra
IS8119A (is) Þétt N-heteróhringlaga efnasambönd og notkun þeirra sem CRF viðtakamótlyfja
IS8137A (is) Kannabinóíð viðtaka bindlar og notkun þeirra
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
DK1691837T3 (da) IP-10-antistoffer og anvendelse heraf
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
IS8526A (is) CRF viðtakamótlyf og aðferðir tengdar þeim
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
NO20054453L (no) P38 inhibitorer og fremgangsmater for anvendelse derav
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
IS7040A (is) 5-HT viðtakabindlar og notkun þeirra
IS8146A (is) Setnar 3-alkýl og 3-alkenýl asetidín afleiður
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
DK1483247T3 (da) Arylsubstituerede pyrimidiner og anvendelsen deraf
DK1527067T3 (da) 4-Trifluormethylpyrazolylsubstituerede pyridiner og pyrimidiner
NO2016020I1 (no) Imidacloprid og Flumetrin
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
NO20031997D0 (no) CRF-reseptor-antagonist og metoder relatert dertil
NO20044012D0 (no) Fremgangsmate og et system
FI20060188L (fi) Modifioidut IL-4-muteiinin reseptorin antagonistit
NO20043799L (no) 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister